Bristol-Myers Squibb vs JPMorgan Chase: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Bristol-Myers Squibb and JPMorgan Chase side by side

1. 1799JPMorgan Chase

   Manhattan Company Chartered

   Aaron Burr and Alexander Hamilton led the effort to obtain a New York charter for the Manhattan Company.

2. 1858Bristol-Myers Squibb

   Edward Robinson Squibb opens his Brooklyn laboratory

   Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.

3. 1871JPMorgan Chase

   Drexel, Morgan & Co. Formed

   J. Pierpont Morgan and Anthony Drexel formed Drexel, Morgan & Co. in New York. The partnership developed into J.P. Morgan & Co., creating the Morgan banking lineage that would remain separate from Chase until the companies combined in 2000.

4. 1887Bristol-Myers Squibb

   Bristol and Myers buy the Clinton Pharmaceutical Company

   Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.

5. 1898Bristol-Myers Squibb

   Bristol, Myers and Company is named

   The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.

6. 1907JPMorgan Chase

   Panic of 1907

   During the Panic of 1907, J. Pierpont Morgan organized bankers and other private participants to support strained financial institutions. The episode became a defining part of the Morgan firm's history in an era before the Federal Reserve existed.

7. 1944Bristol-Myers Squibb

   Penicillin at wartime scale

   Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.

8. 1955JPMorgan Chase

   Chase Manhattan Created

   The Bank of the Manhattan Company merged with Chase National Bank to form Chase Manhattan Bank. This combination joined the firm's oldest 1799 predecessor with the Chase name and created the institution that later merged with J.P. Morgan.

9. 1989Bristol-Myers Squibb

   Bristol-Myers and Squibb merge

   Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.

10. 2000JPMorgan Chase

    Chase and J.P. Morgan Merge

    Chase Manhattan and J.P. Morgan & Co. completed their merger, combining commercial and consumer banking with investment banking and institutional services. JPMorgan Chase identifies this transaction as the formation of the modern company.

11. 2004JPMorgan Chase

    Bank One Merger

    JPMorgan Chase completed its $58.546 billion stock-for-stock merger with Bank One on July 1.

12. 2006Bristol-Myers Squibb

    CEO Peter Dolan removed over the Plavix deal

    After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.

13. 2006JPMorgan Chase

    Jamie Dimon Becomes CEO

    Jamie Dimon succeeded William B. Harrison Jr. as chief executive on January 1. Dimon had joined JPMorgan Chase as president and chief operating officer when the Bank One merger closed and became chairman one year after becoming CEO.

14. 2008JPMorgan Chase

    Bear Stearns Acquired

    JPMorgan Chase completed its acquisition of Bear Stearns during the financial crisis.

15. 2008JPMorgan Chase

    Washington Mutual Operations Acquired

    After Washington Mutual Bank entered FDIC receivership, JPMorgan Chase paid $1.9 billion to acquire its banking operations, including assets, deposits, and qualified financial contracts under the transaction terms.

16. 2009Bristol-Myers Squibb

    Medarex bought and Mead Johnson split off

    BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.

17. 2011Bristol-Myers Squibb

    FDA approves Yervoy

    Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.

18. 2012Bristol-Myers Squibb

    FDA approves Eliquis

    The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.

19. 2014Bristol-Myers Squibb

    FDA approves Opdivo

    The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.

20. 2019Bristol-Myers Squibb

    Celgene acquisition closes

    BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.

21. 2020Bristol-Myers Squibb

    MyoKardia deal and a GAAP loss

    BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.

22. 2022Bristol-Myers Squibb

    Turning Point bought as Revlimid generics arrive

    BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.

23. 2023Bristol-Myers Squibb

    Chris Boerner becomes CEO

    Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.

24. 2023JPMorgan Chase

    First Republic Acquired from FDIC

    JPMorgan Chase acquired the substantial majority of First Republic Bank's assets and assumed deposits and certain liabilities from the FDIC.

25. 2024Bristol-Myers Squibb

    Karuna, Mirati and RayzeBio close; Cobenfy approved

    The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.

26. 2025Bristol-Myers Squibb

    BioNTech partnership, Orbital deal and $48.2B revenue

    BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.

27. 2025JPMorgan Chase

    FY2025 Net Revenue of $182.447B

    JPMorgan Chase reported U.S. GAAP total net revenue of $182.447 billion and net income of $57.048 billion. Its managed, fully taxable-equivalent segment presentation reported $185.581 billion of total net revenue across CCB, CIB, AWM, and Corporate.

28. 2026Bristol-Myers Squibb

    Guidance raised and merger reports denied

    On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.

29. 2026JPMorgan Chase

    Chase to Become Apple Card Issuer

    On January 7, 2026 Apple and Chase announced that Chase will replace Goldman Sachs as Apple Card issuer over about 24 months.

30. 2026JPMorgan Chase

    Co-Presidents Named

    Doug Petno and Troy Rohrbaugh were named co-presidents in June 2026, and Marianne Lake announced her retirement.

Acquisitions

Questions about Bristol-Myers Squibb vs JPMorgan Chase